Report cover image

Retinitis Pigmentosa: Market View

Publisher GlobalData
Published Jan 09, 2026
Length 104 Pages
SKU # GBDT20939874

Description

Retinitis Pigmentosa: Market View

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Retinitis Pigmentosa Therapeutics.
  • In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of RP, representing a large portion of global cases.
  • Currently, the RP market is largely reliant on off-label and symptomatic approaches.
  • The RP pipeline holds 102 molecules, with no assets in the pre-registration stage, four assets in Phase III development, and another 21 in Phase II.
  • Over the past decade, 133 clinical trials have been conducted in RP. The year with the most studies initiated was 2024, with 20 trials, followed by 2019 and 2021 with 13 trials.
  • During the past 32 months, 10 mergers and acquisitions and 10 strategic alliances involving companies developing RP assets were completed globally.
  • The RP market will likely see an influx of drugs in the near term, with four products in Phase III development and no products in pre-registration.
Scope

GlobalData’s Retinitis Pigmentosa: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Retinitis Pigmentosa Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Retinitis Pigmentosa Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

104 Pages
    • What do Physicians Think?
    • Disease Etiology
    • Epidemiology Overview - Diagnosed Prevalent Cases of RP in 2024 and 2029
    • KOL Insights - Patient Population
    • Management Algorithm
    • KOL Insights - Treatment Guidelines
    • KOL Insights - Diagnosis and Treatment Management
    • Marketed Drugs - Leading Marketed Drugs in RP
    • KOL Insights - Marketed Products
    • Marketed Drug Profile - Novartis's Luxturna
    • KOL Insights - Unmet Needs in RP
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Luxturna
    • KOL Insights - Pricing and Reimbursement
    • Pipeline Drugs Overview - Mid- to Late-Stage Pipeline Drugs in RP
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by MOA
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drug Profile - Ocugen's baluretgene parvec - Sales Forecast
    • Pipeline Drug Profile - Ocugen's baluretgene parvec - Summary
    • Pipeline Drug Profile - Johnson & Johnson's botaretigene sparoparvovec - Sales Forecast
    • Pipeline Drug Profile - Johnson & Johnson's botaretigene sparoparvovec - Summary
    • Pipeline Drug Profile - Beacon Therapeutics' laruparetigene zovaparvovec
    • Pipeline Drug Profile - Beacon Therapeutics' laruparetigene zovaparvovec - Summary
    • Pipeline Drug Profile - Nanoscope Therapeutics' sonpiretigene isteparvovec - Sales Forecast
    • Pipeline Drug Profile - Nanoscope Therapeutics' sonpiretigene isteparvovec - Summary
    • Pipeline Drugs - PTSR and LoA in Ophthalmology Disorders & RP
    • Pipeline Drugs - PTSR and LoA in RP
    • KOL Insights - Pipeline Drugs
    • KOL Insights - Clinical Trials
    • Clinical Trials in RP - Historical Overview by Phase
    • Clinical Trials in RP - Historical Overview by Sponsor Type
    • Clinical Trials in RP - Overview by Phase
    • Clinical Trials in RP - Overview by Status
    • Clinical Trials in RP - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in RP - Trials with a Virtual Component
    • Clinical Trials in RP - Top 20 Biomarkers by Trial Phase
    • Clinical Trials in RP - Geographic Overview
    • Clinical Trials in RP - Single-Country and Multinational Trials by Region
    • Clinical Trials in RP - Top Sponsors with Breakdown by Phase
    • Clinical Trials in RP - Top Sponsors with Breakdown by Status
    • Clinical Trials in RP - Overview by Endpoint Status
    • Clinical Trials in RP - Overview by Race and Ethnicity of Trial Participants
    • Clinical Trials in RP - Enrollment Data
    • Clinical Trials in RP - Overview of Sites by Geography
    • Clinical Trials in RP - Top 20 Countries for Trial Sites
    • Clinical Trials in RP - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for RP
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in RP by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in RP
    • Commercial Assessment - Key Market Players in RP
    • Future Market Catalysts - Upcoming Market Catalysts in RP
    • Primary Research: KOL Information
    • Methodology - Sales Forecasts
    • Methodology
    • Methodology - Pricing and Reimbursement
    • Methodology - PTSR and LoA Analysis
    • About the Authors

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us